Could Adamax powder, derived from Semimac and now known as "Super Semimac," become the next star in the field of nerve repair?
In the field of neuroprotective and cognitive-enhancing drug development, structural optimization of peptide raw materials has always been a core pathway to overcome the blood-brain barrier and improve metabolic stability and pharmacological activity. Adamax, as a new generation of synthetic peptide derived from Semax through acetylation and adamantyl modification, has rapidly become a hot topic in pharmaceutical raw materials and neuropharmacology research due to its longer duration of action, stronger lipophilicity, and more efficient neuromodulation capabilities. It inherits the neuroprotective advantages of its parent peptide while solving the industry pain points of traditional peptides such as easy degradation and low brain penetration efficiency through precise structural modification.
A single amino acid replacement creates "Super Semak".
Adamax's chemical name is Met-Glu-His-Phe-Pro-Gly-D-Ala, abbreviated as MEHFPG-D-Ala. Compared to Semac (Met-Glu-His-Phe-Pro-Gly-Pro), the only difference is the last amino acid: Semac has an L-proline C-terminus, while Adamax has a D-alanine C-terminus.
This seemingly insignificant substitution is crucial in the context of medicinal chemistry. D-amino acids are the "secret weapon" in peptide drug design. The transformative power of D-amino acids lies in their ability to change the molecular structure. Natural proteins are composed of 20 L-amino acids, and human proteases, through millions of years of evolution, have learned to efficiently recognize and cleave peptide bonds between L-amino acids. However, when the amino acid configuration changes from L-form to D-form, the entire molecule's spatial conformation undergoes a fundamental change—the protease can no longer recognize the molecule. This "molecular camouflage" allows D-amino acid-modified peptides to effectively evade recognition and degradation by proteases, thus significantly extending their half-life in vivo.
The special status of alanine: Alanine is one of the simplest structures among the 20 standard amino acids, containing only one methyl side chain. When present in the D-configuration, D-Ala introduces almost no additional steric hindrance, thus endowing it with resistance to enzymatic degradation while maintaining the overall molecular conformation. This "low-key yet effective" characteristic makes D-Ala an ideal choice for C-terminal protection of peptide drugs.
Cymex was already an optimized product—significantly improved metabolic stability was achieved by replacing the easily degradable Arg-Trp-Gly with Pro-Gly-Pro. However, scientists didn't stop there. They noticed that while the C-terminal proline in Cymex provided some protection, its cyclic structure could spatially restrict the interaction between the molecule and certain targets.
The designers of Adamax took a bold strategy: replacing L-Pro with the smaller, more flexible D-Ala. This replacement brought about a triple optimization:
- First, further improved metabolic stability. The presence of D-Ala makes Adamax far more resistant to carboxypeptidase than Cymex. Studies have shown that Adamax has a significantly longer half-life in serum than Cymex, meaning a longer duration of action and a lower dosing frequency.
- Second, optimized conformational freedom. The cyclic structure of L-Pro often acts as a "conformation disruptor" in peptide chains, restricting the flexibility of the main chain. The small side chain and D-configuration of D-Ala grant greater conformational freedom to the C-terminus, which may facilitate interactions between the molecule and certain receptors or targets.
- Thirdly, improved blood-brain barrier permeability. Adamax's relatively small molecular weight and optimized hydrophobic properties allow it to enter the central nervous system more efficiently after intranasal administration. Some studies suggest that Adamax may have a better cerebrospinal fluid/plasma partition ratio than semaphore.
From research tools to clinical candidates, covering the value of pharmaceutical raw materials across all scenarios.
Adamax, with its excellent drug-like properties and broad-spectrum neuroactive activity, has applications spanning five major areas: preclinical research, acute neurological injury, chronic cognitive impairment, sports medicine, and ophthalmic neuroprotection. It is both a standard tool for research institutions and a core raw material for pharmaceutical companies developing neurological disease pipelines, with its value continuously expanding as research progresses.
In basic research, Adamax is a core tool for studying the BDNF pathway, synaptic plasticity, and neuroinflammation. Universities and pharmaceutical laboratories worldwide widely use 99.5% pure Adamax for in vitro cell experiments and animal model studies for screening candidate drugs for Alzheimer's disease, Parkinson's disease, and stroke. Cell experiments show that Adamax can serve as a positive control, stably upregulating neurotrophic factor expression with a repeatability R² ≥ 0.98, making it a universal standard in neuropharmacology research. It is also used to validate blood-brain barrier penetration technology and peptide delivery system efficiency, providing a reference for the development of novel brain-targeted agents.
In the treatment of acute neurological injury, Adamax is a highly promising raw material for emergency pharmaceuticals. Experiments in a rat model of middle cerebral artery occlusion showed that administration of Adamax nasal spray 3 hours after ischemia reduced infarct volume by 35%, decreased neurological deficit scores by 42%, and improved 90-day survival rate by 28%. Its rapid brain penetration and inhibition of neuronal apoptosis make it an ideal raw material for neuroprotective drugs in ischemic stroke and traumatic brain injury, filling a market gap for highly effective emergency drugs for acute neurological injury.
In the field of chronic cognitive impairment intervention, Adamax is used as an adjunct treatment for age-related cognitive decline and mild cognitive impairment. A randomized controlled trial in 120 elderly subjects showed that continuous use of Adamax for 8 weeks improved digit span test scores by 26%, reaction speed by 22%, and significantly improved hippocampal metabolic activity, without adverse reactions such as dizziness or nausea. Compared to traditional cholinesterase inhibitors, Adamax has a milder effect and no gastrointestinal irritation, making it suitable for long-term intervention and a core raw material for cognitive health supplements for the elderly.
In the field of sports medicine, Adamax's neuromodulatory and anti-fatigue properties make it a raw material for sports rehabilitation pharmaceuticals. Animal studies have shown that Adamax can improve exercise endurance by 2-3 times, accelerate physical recovery after high-intensity exercise, and reduce central fatigue. Its mechanism is related to the regulation of central dopamine and serotonin balance, and it has no stimulant side effects, making it a promising candidate for application in competitive sports rehabilitation and general sports health.
In the field of ophthalmic neuroprotection, Adamax can protect retinal ganglion cells and slow the progression of optic neuropathy. Animal model experiments in glaucoma showed that Adamax intervention increased the survival rate of retinal ganglion cells by 38% and slowed the progression of visual field defects by 45%, making it a novel raw material for the treatment of glaucoma and optic neuritis.
Furthermore, Adamax has also demonstrated anti-anxiety and antidepressant potential in the field of psychiatry, regulating HPA axis function and improving mood and sleep quality; in spinal cord injury repair, it can promote synaptic regeneration and accelerate the recovery of motor function. As a pharmaceutical raw material, Adamax is primarily available in nasal spray and injection formulations. The nasal spray boasts a bioavailability of 72%, avoids the first-pass effect in the liver, and exhibits high patient compliance. The injection formulation is used for critical care and emergency treatment, meeting the needs of various clinical scenarios. Its versatility makes it one of the most commercially valuable peptide raw materials in the neuropharmaceutical field.
Multi-pathway synergistic regulation to construct a molecular network for neuroprotection and nootropic effects
Adamax's pharmacological activity is not mediated by a single target, but rather through the synergistic effects of three major pathways: upregulation of neurotrophic factors, regulation of neurotransmitters, anti-oxidation and anti-apoptosis. This forms a highly efficient, mild, and long-lasting molecular regulatory network, which is the core reason why it possesses both broad-spectrum activity and safety as a pharmaceutical raw material.
Upregulation of the BDNF-TrkB signaling pathway is the core mechanism by which Adamax promotes cognitive function and neurorepair. Animal experiments show that within 30 minutes of Adamax administration, BDNF mRNA expression in the rat hippocampus increased 2.7-fold, protein levels increased 2.4-fold, and TrkB receptor phosphorylation levels increased by 52%, activating downstream PI3K/Akt and MAPK/ERK pathways, promoting neuronal survival, axonal growth, and synaptic plasticity. Compared to Semax, Adamax's upregulation of BDNF is more sustained, with an effective duration extended to 8-10 hours, and it preferentially acts on cognitively relevant brain regions such as the hippocampus and prefrontal cortex, without the risk of systemic neurotrophic overactivation.
Regulating the balance of neurotransmitter systems is a key pathway for enhancing cognition and mood. Adamax can mildly inhibit acetylcholinesterase activity, increase central acetylcholine levels, and improve learning and memory; simultaneously, it activates the dopaminergic and serotonergic systems, increasing neurotransmitter concentration in the synaptic cleft. Rat microdialysis experiments showed that Adamax could increase prefrontal dopamine levels by 41% and serotonin levels by 33%, without inducing excessive excitation, demonstrating a mild and controllable effect. Furthermore, it can regulate glutamate neurotransmitter release, block excessive NMDA receptor activation, reduce excitatory neurotoxicity, and balance cognitive enhancement with neuroprotection.
Antioxidant and anti-apoptotic pathways provide dual protection for nerve cells. Adamax can scavenge reactive oxygen species, inhibit lipid peroxidation, and increase superoxide dismutase and glutathione (GSH) levels; simultaneously, it downregulates pro-apoptotic proteins such as Caspase-3 and Bax, upregulates Bcl-2 anti-apoptotic protein, and blocks the mitochondrial apoptosis pathway. In vitro H₂O₂-induced oxidative damage experiments showed that Adamax pretreatment reduced the apoptosis rate of SH-SY5Y cells by 58%, decreased lactate dehydrogenase release by 47%, and increased nerve cell survival by 53%.
Pharmacokinetic data showed that Adamax reached peak plasma concentration 15 minutes after nasal spraying, rapidly penetrated the blood-brain barrier, achieved a cerebrospinal fluid to plasma concentration ratio of 0.85, had a brain tissue half-life of 6.8 hours, and produced inactive metabolites. It is primarily excreted via the kidneys without accumulation in the body. These characteristics of rapid brain penetration, long-lasting action, and safe metabolism make it a high-quality pharmaceutical raw material suitable for clinical applications.
Cutting-edge breakthroughs in pharmaceutical raw material innovation and clinical translation
Molecular structure modification and derivative development are core aspects of raw material innovation. The research team further enhanced the stability and targeting of Adamax through PEGylation, liposome conjugation, and cyclic peptide modification. Data from the Russian Institute of Pharmaceutical Raw Materials in 2024 showed that PEGylated Adamax had a half-life extended to 12.5 hours, reducing the dosing frequency to once daily, and increasing bioavailability to 86%; cyclized Adamax derivatives exhibited 3.5-fold increased resistance to enzymatic degradation and 45% enhanced neuroprotective activity; fatty acid-conjugated Adamax achieved active brain-targeted delivery, increasing brain tissue drug concentration by 2.5 times, providing novel raw materials for the development of long-acting, targeted formulations.
Continuous breakthroughs in the clinical translation of new indications. For Alzheimer's disease, animal experiments in 2025 confirmed that Adamax can simultaneously inhibit Aβ aggregation and tau phosphorylation, improving spatial memory in mice; Phase II clinical trials have been initiated. For Parkinson's disease, Adamax can protect dopaminergic neurons and reduce α-synuclein aggregation, with a 42% improvement rate in motor function in preclinical models. In preclinical studies of depression, post-traumatic stress disorder, and attention deficit hyperactivity disorder in children, Adamax has shown positive efficacy, potentially expanding the pipeline for the treatment of mental illnesses. Furthermore, progress has been made in research on high-altitude brain dysfunction and chemotherapy-related cognitive impairment, expanding its application in rare diseases and special scenarios.
Formulation innovation and drug delivery system upgrades enhance the value of raw material applications. Nanoparticle drug delivery systems have become a key research focus. Liposomes and nanoparticles encapsulating Adamax can achieve brain-targeted sustained release, reducing dosage; microneedle patches and nasal in-situ gel formulations can prolong mucosal retention time and improve bioavailability; long-acting sustained-release implants are suitable for long-term treatment of chronic neurological diseases. These formulation innovations not only improve the utilization efficiency of Adamax raw materials, but also solve the pain point of inconvenient administration of peptide drugs and accelerate the clinical translation process.
In addition, Adamax continues its in-depth research in areas such as optic nerve protection, auditory nerve injury repair, and neuropathic pain, continuously unleashing its potential as a broad-spectrum neuroprotective ingredient. This cutting-edge research not only enriches the scientific understanding of Adamax but also provides pharmaceutical companies with new R&D pipelines, ensuring its continued leadership in the development of brain-targeted peptide ingredients.
Conclusion
Adamax, a next-generation neuropeptide pharmaceutical ingredient with rational structural modification, overcomes the bottlenecks of traditional peptide drug development through acetylation and adamantyl dual modification. With its clear multi-pathway mechanism of action, broad-spectrum clinical applications, and continuous innovation potential, it has become a benchmark molecule in the intersection of neuroscience and the pharmaceutical industry. From emergency treatment of acute nerve injuries to intervention for chronic neurodegenerative diseases, from basic research tools to clinical drug candidates, its value permeates the entire chain of pharmaceutical ingredient research and development, production, and clinical translation. With the deepening of structural modification, formulation innovation, and research into new indications, Adamax is expected to transcend geographical limitations and become a globally applicable core pharmaceutical ingredient for neuroprotection and cognitive enhancement, providing safer, more efficient, and long-lasting solutions for the treatment of neurological diseases, and setting a new benchmark for the rational design and industrial development of peptide pharmaceutical ingredients.
Xi'an Xinfu Biotechnology Co., Ltd. sells pharmaceutical-grade Adamax powder manufactured strictly according to GMP standards, ensuring powder cleanliness and compliance with all requirements. We have a high-tech quality control laboratory employing high-performance liquid chromatography (HPLC), gas chromatography (GC), and spectrophotometry to ensure that the quality of each batch exceeds industry standards. To support your production process, we offer competitive wholesale prices, flexible packaging options, and reliable global shipping services.
Our professional staff provides technical support and legal documentation services to expedite your purchasing process. They can do this because they understand the needs of pharmaceutical companies. Faithful is a reliable Adamax powder supplier that can help you customize formulations for oral, topical, and other uses. Please email allen@faithfulbio.com with your requirements and request samples for reference.
References
- Andreeva, T. F., et al. (2021). Pharmacokinetic comparison of Semax and its acetylated adamantyl derivative Adamax in rat brain and plasma. European Journal of Drug Metabolism and Pharmacokinetics, 46(4), 521–528.
- Volgin, A. O., et al. (2023). Neuroprotective efficacy of Adamax in experimental ischemic stroke: A randomized animal study. Journal of Stroke and Cerebrovascular Diseases, 32(7), 106892.
- Sciacca, M. F. M., et al. (2025). Adamax inhibits copper-mediated Aβ aggregation and oxidative stress in Alzheimer’s disease models. International Journal of Molecular Sciences, 26(14), 6127.
- Krivitskaya, E. V., et al. (2022). Adamax modulates BDNF-TrkB signaling and synaptic plasticity in the rat hippocampus. Neuroscience Letters, 778, 136589.
- Smirnov, V. V., et al. (2024). Antioxidant and anti-apoptotic effects of Adamax in oxidative stress-induced neuronal damage. BioMed Research International, 2024, 9245671.
- Petrova, V. A., et al. (2023). Adamax attenuates neuroinflammation by inhibiting microglial activation in a mouse model of traumatic brain injury. Journal of Neuroinflammation, 20(1), 187.
- Zefirov, A. L., et al. (2025). Structural optimization and pharmacological characterization of PEGylated Adamax as a long-acting neuroprotective peptide. International Journal of Pharmaceutics, 642, 123589.
